评估使用del Nido停搏液术后临床结局的性别差异
本研究回顾性纳入2014年1月至2019年12月在本机构使用del Nido停搏液行冠状动脉旁路移植或冠状动脉旁路移植/瓣膜手术的患者2118例,倾向匹配后队列1252例(女性459例,男性793例)。多因素逻辑回归显示生物学性别与复合主要终点(30天死亡率或术后机械支持装置需求)无关(OR=0.898,P=0.779),Gamma模型显示患者出手术室时血管活性-正性肌力评分无性别差异(exp[est]=1.394,P=0.189)。结论认为当前给药剂量的del Nido停搏液心肌保护充分,但需进一步研究停搏液之间的性别差异。
要点
- 倾向匹配后女性459例、男性793例,所有标准化均数差<0.1。
- 生物学性别与复合主要终点无关(OR=0.898,P=0.779)。
- 出手术室时血管活性-正性肌力评分无性别差异(exp[est]=1.394,P=0.189)。
核心结论
- 使用del Nido停搏液后临床结局无显著性别差异,提示当前给药方案心肌保护充分。
- 需进一步研究以明确停搏液之间是否存在性别差异。
研究设计与样本
- 回顾性收集本机构2014年1月至2019年12月使用del Nido停搏液行冠状动脉旁路移植或冠状动脉旁路移植/瓣膜手术的患者2118例。
- 创建倾向匹配队列1252例(女性459例,男性793例,匹配比至1:2,所有标准化均数差<0.1)。
- 采用多因素逻辑回归分析二分类术后结局,Gamma模型分析连续术后结局。
主要发现
- 多因素逻辑回归显示生物学性别与复合主要终点(30天死亡率和/或术后机械支持装置需求)无关(OR=0.898,P=0.779)。
- Gamma模型显示患者出手术室时血管活性-正性肌力评分无性别相关差异(exp[est]=1.394,P=0.189)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: del Nido cardioplegia is used to pharmacologically arrest the heart during cardiac surgery and decrease reperfusion- and ischaemia-related myocardial injury. Studies have demonstrated the physiological differences between male and female hearts, potentially related to cardiac size or myocyte calcium handling; we aimed to assess for between-sex differences in clinical outcomes after receipt of del Nido cardioplegia. METHODS: Patients who underwent coronary artery bypass or coronary artery bypass graft/valve surgery at our institution using del Nido cardioplegia (January 2014 to December 2019) were included (n = 2118). Clinical data were collected retrospectively. After the creation of a propensity-matched cohort (n = 1252), multivariable logistic regression was used to analyse binary postoperative outcomes, and a Gamma model was used for a continuous postoperative outcome. Our primary end-point was a composite end-point comprised of 30-day mortality and/or need for a post-bypass mechanical support device. RESULTS: The final cohort included 459 females and 793 males (matched up to 1:2, all standardized mean differences <0.1). Multivariable logistic regression showed that biological sex was not associated with the composite primary end-point (odds ratio = 0.898, P = 0.779). A Gamma model indicated that there were no sex-related differences in vasoactive-inotropic scores reflecting vasopressor and inotrope usage at the time of patient operating room exit (exp[est] = 1.394, P = 0.189). CONCLUSIONS: Our findings showed no significant between-sex differences in clinical outcomes after receiving del Nido cardioplegia, suggesting adequate myocardial protection as currently administered. Further research is warranted to elicit if there are sex-based differences between cardioplegic solutions. IRB APPROVAL DATE (PROTOCOL NUMBER): 26 May 2021 (AAAR8359).
引用
- Honzel E, Nemeth S, Kazzi BE, et al. Assessing sex-based differences in postsurgical clinical outcomes after use of del Nido cardioplegia. Eur J Cardiothorac Surg. 2022. PMID: 36165688. doi:10.1093/ejcts/ezac472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。